Overview

AMCPR (Augmented-Medication CardioPulmonary Resuscitation) Trial for OHCA

Status:
Unknown status
Trial end date:
2018-07-30
Target enrollment:
Participant gender:
Summary
The investigators aimed to evaluate the effect of AMCPR (Augmented-Medication CardioPulmonary Resuscitation: administration of additional vasopressin to titrate to arterial diastolic blood pressure over 20 mmHg) on cardiopulmonary resuscitation results and outcomes in out-of-hospital cardiac arrest patients.
Phase:
Phase 2
Details
Lead Sponsor:
Asan Medical Center
Treatments:
Arginine Vasopressin
Vasopressins